Shimura K, Ito H, Hibasami H
Jpn J Pharmacol. 1983 Apr;33(2):403-8. doi: 10.1254/jjp.33.403.
On crossed immunoelectrophoresis, human serum C3 (the third component of complement) converted by antitumor polysaccharides (ATSO [antitumor polysaccharide oral], AB-P [Agaricaus blazei polysaccharide], GU-P [Grifora umbellata polysaccharide], PS-K [polysaccharide Kureha] and zymosan) moved faster than native C3, appearing as the 3rd peak. The ratio of height of the 3rd peak to the alpha 2-macroglobulin (alpha 2-M) peak was linearly proportional to the dose of ATSO. At the dose of 500 micrograms/ml antitumor polysaccharides, the ratios were higher than 0.76, and the ratios for the serum treated with polysaccharide of no antitumor activity (dextran and gum arabic) were less than about 0.52. This ratio readily determined in vivo can be used as a measure for the antitumor activity of polysaccharides.
在交叉免疫电泳中,经抗肿瘤多糖(ATSO[口服抗肿瘤多糖]、AB-P[姬松茸多糖]、GU-P[猪苓多糖]、PS-K[云芝多糖K]和酵母聚糖)转化的人血清补体C3(补体第三成分)比天然C3迁移得更快,表现为第三个峰。第三个峰的高度与α2-巨球蛋白(α2-M)峰高度的比值与ATSO剂量呈线性比例关系。在抗肿瘤多糖剂量为500微克/毫升时,该比值高于0.76,而用无抗肿瘤活性的多糖(葡聚糖和阿拉伯树胶)处理的血清的比值小于约0.52。这种可在体内轻松测定的比值可作为多糖抗肿瘤活性的一种衡量指标。